15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Inovio Pharmaceuticals Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $2.50 to $4.00, a moderate spread. The average target of $3.17 sits 124% above the current $1.42. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Inovio Pharmaceuticals Inc.
As of Sep, 2 of 3 firms rate INO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
INO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.18 – $-0.18 · 2 analysts · -35% YoY
Next period, 2 analysts expect Inovio Pharmaceuticals Inc to earn $-0.18 a share (range $-0.18 – $-0.18), versus $-0.28 a year earlier. Full-year consensus is $-0.73, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$666.7K
Range $0 – $2.0M · 2 analysts
Revenue is expected to reach $666.7K (range $0 – $2.0M). Full-year consensus is $666.7K, rising to $50.6M next year.
Top analysts covering Inovio Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INO.
#1
Roger Song
Jefferies · Rank #101
Buy
$3.00+112.0% to target
Overall win rate
43%
+ Follow
#2
Roy Buchanan
JMP Securities · Rank #114
Buy
$12.00+748.1% to target
Overall win rate
49%
+ Follow
#3
Gregory Renza
RBC Capital · Rank #213
Hold
$5.00+253.4% to target
Overall win rate
34%
+ Follow
#4
Raghuram Selvaraju
HC Wainwright & Co. · Rank #312
Hold
$2.50+76.7% to target
Overall win rate
36%
+ Follow
#5
Edward Tenthoff
Piper Sandler · Rank #337
Buy
$4.00+182.7% to target
Overall win rate
29%
+ Follow
INO stock forecast FAQ
What is INO's average 12-month price target?+
The 3 analysts with a live target average $3.17 for Inovio Pharmaceuticals Inc over the next 12 months, ranging from a $4.00 high to a $2.50 low.
Is INO stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for INO?+
The Street-high target is $4.00 (Piper Sandler), and the Street-low is $2.50 (HC Wainwright & Co.). The average of all 3 active targets is $3.17.
How many Wall Street analysts cover INO?+
3 analysts have an active rating on Inovio Pharmaceuticals Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering INO?+
Among analysts who currently cover INO, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #101). Their current call is Buy with a $3.00 target.
What is Inovio Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.18 – $-0.18) across 2 analysts. Full-year EPS is projected at $-0.73, rising to $-0.44 the following year.
How much revenue is Inovio Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $666.7K (range $0 – $2.0M). Full-year revenue is projected at $666.7K, growing to $50.6M next year.
Have analysts been upgrading or downgrading INO lately?+
As of Sep, 2 of 3 firms rate INO a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
